- Home
- MQY vs NTLA Comparison
MQY vs NTLA Comparison
Compare MQY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- NTLA
- Stock Information
- Founded
- MQY 1994
- NTLA 2014
- Country
- MQY United States
- NTLA United States
- Employees
- MQY N/A
- NTLA N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MQY Finance
- NTLA Health Care
- Exchange
- MQY Nasdaq
- NTLA Nasdaq
- Market Cap
- MQY 844.8M
- NTLA 959.4M
- IPO Year
- MQY N/A
- NTLA 2016
- Fundamental
- Price
- MQY $11.90
- NTLA $12.17
- Analyst Decision
- MQY
- NTLA Buy
- Analyst Count
- MQY 0
- NTLA 18
- Target Price
- MQY N/A
- NTLA $50.53
- AVG Volume (30 Days)
- MQY 184.8K
- NTLA 3.1M
- Earning Date
- MQY 01-01-0001
- NTLA 02-27-2025
- Dividend Yield
- MQY 4.73%
- NTLA N/A
- EPS Growth
- MQY N/A
- NTLA N/A
- EPS
- MQY N/A
- NTLA N/A
- Revenue
- MQY N/A
- NTLA $43,086,000.00
- Revenue This Year
- MQY N/A
- NTLA $50.68
- Revenue Next Year
- MQY N/A
- NTLA N/A
- P/E Ratio
- MQY N/A
- NTLA N/A
- Revenue Growth
- MQY N/A
- NTLA N/A
- 52 Week Low
- MQY $9.82
- NTLA $8.96
- 52 Week High
- MQY $12.52
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- MQY 49.50
- NTLA 61.74
- Support Level
- MQY $11.79
- NTLA $8.96
- Resistance Level
- MQY $12.00
- NTLA $12.84
- Average True Range (ATR)
- MQY 0.10
- NTLA 0.73
- MACD
- MQY 0.00
- NTLA 0.39
- Stochastic Oscillator
- MQY 40.62
- NTLA 82.73
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.